1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. New Products | 新产品
  5. NEW2
  6. New2

Fulvestrant R enantiomer

别名: 13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; Fulvestrant R enantiomer; 1807900-80-6; CID 3478439; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-[(R)-4,4,5,5,5-pentafluoropentylsulfinyl]nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1316849-17-8; CID 138106603; SCHEMBL408338; 氟维司群; 抗雌激素; 氟维斯群; 氟维思群; 氟维司琼
目录号: V32201 纯度: ≥98%
COA 产品数据 产品说明书 SDS
氟维司群 R 对映体是氟维司群的 R 异构体（ICI182780；ZD-9238；ZM182780；ICI-182780；ZD9238；ZM-182780；Faslodex），是一种合成的强效雌激素受体（ER）拮抗剂，被批准用于治疗激素绝经后妇女的受体（HR）阳性乳腺癌。
Fulvestrant R enantiomer CAS号: 1807900-80-6
产品类别: New2
产品仅用于科学研究，不针对患者销售
规格 价格
500mg
1g
Other Sizes
大包装询价
020-31522723 sales@invivochem.cn

Other Forms of Fulvestrant R enantiomer:

  • Fulvestrant 3-β-D-Glucuronide
  • Fulvestrant-d3 (ICI 182780-d3; ZD 9238-d3; ZM 182780-d3)
  • Fulvestrant-d5 (ICI 182780-d5; ZD 9238-d5; ZM 182780-d5)
  • 氟维司群
  • 氟维司群S-异构体
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
产品描述
氟维司群 R 对映体是氟维司群的 R 异构体（ICI182780；ZD-9238；ZM182780；ICI-182780；ZD9238；ZM-182780；Faslodex），它是一种合成的有效雌激素受体（ER）拮抗剂，被批准用于治疗绝经后妇女激素受体（HR）阳性乳腺癌的发病率。
生物活性&实验参考方法
靶点
Estrogen Receptor/ER
体外研究 (In Vitro)
13-甲基-7-[9-（4,4,5,5,5-五氟戊基亚磺酰基）壬基]-6,7,8,9,11,12,14,15,16,17-十氢环戊[a]菲-3,17-二醇是一种类固醇。它具有雌激素的作用。
Fulvestrant（Faslodex®）由6-脱氢诺龙乙酸酯分四步合成（总收率35%）。在关键的C-C键形成步骤[1]中，使用了由市售9-溴壬-1-烯衍生的二茂锆的催化剂控制、室温、非对映选择性1,6-加成反应。
体内研究 (In Vivo)
在大鼠和猪尾猴中，单次注射ICI 182780油悬浮液后，持续的抗雌激素作用都很明显。在体内，ICI 182780在裸鼠体内用MCF-7和Br10人乳腺癌异种移植物证明了其抗肿瘤活性。单次注射ICI 182780提供的抗肿瘤疗效相当于至少4周的每日他莫昔芬治疗。ICI 182780的特性将这种纯抗雌激素确定为主要候选药物，用于评估完全停止雌激素对内分泌反应性人类乳腺癌症的潜在治疗益处[2]。
药代性质 (ADME/PK)
吸收、分布和排泄
氟维司群主要经肝胆途径快速清除，主要通过粪便排泄（约占90%）。肾脏清除率可忽略不计（小于1%）。
肌注后约7天达到3～5 L/kg的血浆峰浓度，并持续至少1个月。通常情况下，每月肌注一次后，3-6个月即可达到稳态血浆氟维司群浓度。
氟维司群似乎能迅速且广泛分布，主要分布于血管外间隙
99%（主要为极低密度脂蛋白、低密度脂蛋白和高密度脂蛋白脂蛋白组分）。
已证实氟维司群可透过胎盘并分布于大鼠乳汁中。
有关氟维司群（共8项）的更多吸收、分布和排泄（完整）数据，请访问HSDB记录页面。
代谢/代谢物
氟维司群的代谢似乎涉及多种可能的生物转化途径的组合，类似于内源性类固醇的代谢途径，包括氧化、芳香族羟基化、与葡萄糖醛酸和/或硫酸盐在类固醇核的2、3和17位结合、侧链亚砜代谢的氧化。在抗雌激素模型中，其活性与氟维司群相似或较低。已鉴定的代谢物。使用人肝制剂和重组人酶的研究表明，细胞色素P-450 3A4 (CYP 3A4) 是参与氟维司群氧化的唯一P-450同工酶；然而，P-450和非P-450途径在体内的相对贡献尚不清楚。
肌内注射和静脉注射14C标记的氟维司群后，已确定了氟维司群在人体内的环境分布。生物转化。氟维司群的代谢似乎涉及多种可能的生物转化途径，类似于内源性类固醇的代谢途径，包括氧化、芳香族羟基化、在类固醇核的2、3和17位与葡萄糖醛酸和/或硫酸结合，以及侧链亚砜的氧化代谢。
氟维司群代谢产物的药理活性与母体化合物相似或更低。
体外研究表明，CYP3A4是参与氟维司群氧化的唯一酶；然而，目前尚不清楚体内CYP和非CYP途径的相对贡献。
生物半衰期
40天
氟维司群的消除半衰期约为40天。
毒性/毒理 (Toxicokinetics/TK)
肝毒性
据称，高达 15% 的患者会出现血清酶升高，但这些升高通常无症状、短暂且程度较轻，很少需要调整剂量或停止氟维司群治疗。仅有 1% 至 2% 的患者出现 ALT 升高超过正常值上限 5 倍的情况。然而，关于氟维司群治疗期间血清酶升高的具体时间和过程尚未有详细描述。此外，在氟维司群上市前的对照试验中，未报告任何伴有黄疸的临床明显肝损伤病例，自其在美国获批并广泛应用以来，也未见相关病例报道。然而，氟维司群的产品标签提到“肝炎和肝衰竭的报告并不常见（
可能性评分：E（未经证实但怀疑是临床上明显的肝损伤的原因）。
蛋白质结合
99%（主要与VLDL、LDL和HDL结合）
参考文献

[1]. An alternative synthesis of the breast cancer drug fulvestrant (Faslodex®): catalyst control over C-C bond formation. Chem Commun (Camb). 2015;51(80):14866-14868.

[2]. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867-3873.
其他信息
治疗用途
抗肿瘤药；激素雌激素拮抗剂
适用于治疗绝经后妇女激素受体阳性转移性乳腺癌，且在接受抗雌激素治疗氟维司群后病情进展。 /包含于美国产品标签/
药物警告
氟维司群禁用于/妊娠、已知对氟维司群、苯甲醇或制剂中任何成分过敏者。
由于氟维司群需肌注给药，因此不应用于出血性疾病或血小板减少症患者，或正在接受抗凝治疗的患者。
临床研究中，接受该药物治疗的患者中，分别约有 52%、15%、14%、18% 和 16% 的患者出现胃肠道不良反应（例如恶心、呕吐、便秘、腹泻、腹痛）、头痛、背痛、血管舒张（潮热）和咽炎。
其他不良反应发生率在 5% 至 23% 之间（按发生频率降序排列），包括：乏力、疼痛、营养不良、骨痛、呼吸困难、注射部位疼痛、咳嗽加剧、盆腔疼痛、厌食、外周水肿、皮疹、胸痛、流感样症状、头晕、失眠、发烧、感觉异常、尿路感染、抑郁、焦虑和出汗。在一项研究中，接受单次 5 mL 氟维司群注射的患者中有 7% 报告出现轻微的短暂疼痛和炎症；在另一项研究中，接受两次 2.5 mL 氟维司群注射的患者中有 27% 报告出现注射部位反应。
有关氟维司群（共 7 条）的更多药物警告（完整）数据，请访问 HSDB 记录页面。
药效学
用于肌注的氟维司群是一种雌激素受体拮抗剂，不具有已知的激动剂作用。

本实验室之前的研究描述了一系列 7 种具有纯抗雌激素活性的雌二醇 α-烷基酰胺类似物，例如 ICI 164,384。一种名为7α-[9-(4,4,5,5,5-五氟戊基亚磺酰基)壬基]雌甾-1,3,5(10)-三烯-3,17β-二醇 (ICI 182,780) 的新化合物已被发现，其抗雌激素活性显著增强，并保留了纯雌激素拮抗活性。在未成熟大鼠中，ICI 182,780 的抗子宫生长活性比 ICI 164,384 高出10倍以上（ICI 164,384 的50%有效剂量分别为0.06 mg/kg和0.9 mg/kg）。这种体内活性的数量级提升也部分归因于其对雌激素受体的内在活性。与雌二醇（1.0）相比，ICI 182,780 和 ICI 164,384 的相对结合亲和力分别为 0.89 和 0.19。同样，在 MCF-7 人乳腺癌细胞中，ICI 182,780 的体外生长抑制效力也高于 ICI 164,384，其 50% 抑制浓度分别为 0.29 nM 和 1.3 nM。ICI 182,780 对 MCF-7 细胞生长的抑制作用强于 4'-羟基他莫昔芬，在 4'-羟基他莫昔芬达到 50% 最大抑制率的条件下，ICI 182,780 可使细胞数量减少 80%。这种更高的抑制效力体现在，与他莫昔芬处理的细胞相比，ICI 182,780 处理的细胞培养物中参与 DNA 合成的细胞比例显著降低。 [2]
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C32H47F5O3S
分子量
606.77080655098
精确质量
606.316
元素分析
C, 63.34; H, 7.81; F, 15.66; O, 7.91; S, 5.28
CAS号
1807900-80-6
相关CAS号
Fulvestrant;129453-61-8;Fulvestrant (S enantiomer);1316849-17-8
PubChem CID
104741
外观&性状
White powder ... the solution for injection is a clear, colorless to yellow, viscous liquid
LogP
9.2
tPSA
76.7
氢键供体(HBD)数目
2
氢键受体(HBA)数目
9
可旋转键数目(RBC)
14
重原子数目
41
分子复杂度/Complexity
854
定义原子立体中心数目
6
SMILES
S(CCCC(C(F)(F)F)(F)F)(CCCCCCCCCC1CC2C=C(C=CC=2C2CCC3(C)C(CCC3C21)O)O)=O
InChi Key
VWUXBMIQPBEWFH-WCCTWKNTSA-N
InChi Code
InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
化学名
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
别名
13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; Fulvestrant R enantiomer; 1807900-80-6; CID 3478439; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-[(R)-4,4,5,5,5-pentafluoropentylsulfinyl]nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1316849-17-8; CID 138106603; SCHEMBL408338;
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.6481 mL 8.2404 mL 16.4807 mL
5 mM 0.3296 mL 1.6481 mL 3.2961 mL
10 mM 0.1648 mL 0.8240 mL 1.6481 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
CTID: NCT02216786
Phase: Phase 2    Status: Completed
Date: 2024-12-02
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
CTID: NCT06428396
Phase: Phase 2    Status: Recruiting
Date: 2024-12-02
A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)
CTID: NCT06680921
Phase: Phase 3    Status: Recruiting
Date: 2024-11-29
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
CTID: NCT05467891
Phase: Phase 2    Status: Recruiting
Date: 2024-11-27
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
CTID: NCT04544189
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-27
View More

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
CTID: NCT01602380
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-27

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
CTID: NCT05554354
Phase: Phase 2    Status: Recruiting
Date: 2024-11-27
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
CTID: NCT02675231
Phase: Phase 2    Status: Completed
Date: 2024-11-26
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
CTID: NCT04556773
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-11-25
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
CTID: NCT05768139
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-25
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
CTID: NCT06702618
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-25
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
CTID: NCT05646862
Phase: Phase 3    Status: Recruiting
Date: 2024-11-25
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
CTID: NCT06257264
Phase: Phase 1    Status: Recruiting
Date: 2024-11-22
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
CTID: NCT06239467
Phase: Phase 1    Status: Recruiting
Date: 2024-11-22
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
CTID: NCT05654623
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-22
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
CTID: NCT05564377
Phase: Phase 2    Status: Recruiting
Date: 2024-11-21
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
CTID: NCT06105632
Phase: Phase 3    Status: Recruiting
Date: 2024-11-19
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
CTID: NCT06380751
Phase: Phase 3    Status: Recruiting
Date: 2024-11-19
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
CTID: NCT04557449
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-18
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
CTID: NCT06110793
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-18
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
CTID: NCT06065748
Phase: Phase 3    Status: Recruiting
Date: 2024-11-15
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
CTID: NCT03056755
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-14
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
CTID: NCT05038735
Phase: Phase 3    Status: Recruiting
Date: 2024-11-14
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
CTID: NCT03238196
Phase: Phase 1    Status: Completed
Date: 2024-11-14
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
CTID: NCT04524000
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-14
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
CTID: NCT03424005
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-13
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
CTID: NCT06494150
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-13
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
CTID: NCT04579380
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
CTID: NCT05226871
Phase: Phase 2    Status: Recruiting
Date: 2024-11-12
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
CTID: NCT04862663
Phase: Phase 3    Status: Recruiting
Date: 2024-11-08
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
CTID: NCT04060862
Phase: Phase 1    Status: Terminated
Date: 2024-11-08
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
CTID: NCT01560416
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-06
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
CTID: NCT04214288
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-06
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
CTID: NCT05090358
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-04
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
CTID: NCT02778685
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-30
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
CTID: NCT04762979
Phase: Phase 2    Status: Recruiting
Date: 2024-10-30
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
CTID: NCT05735080
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-10-29
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
CTID: NCT03685331
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-29
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
CTID: NCT06663072
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-10-29
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced And/or Metastatic Breast Cancer
CTID: NCT06515470
Phase: Phase 1    Status: Recruiting
Date: 2024-10-29
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
CTID: NCT06120283
Phase: Phase 1    Status: Recruiting
Date: 2024-10-28
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
CTID: NCT06253195
Phase: Phase 1    Status: Recruiting
Date: 2024-10-28
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
CTID: NCT05307705
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-26
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
CTID: NCT04059484
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-22
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
CTID: NCT03280563
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-10-21
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
CTID: NCT04975308
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-18
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
CTID: NCT05601440
Phase: Phase 2    Status: Recruiting
Date: 2024-10-18
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
CTID: NCT02860000
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-18
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
CTID: NCT05306340
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-16
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
CTID: NCT02763566
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-16
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
CTID: NCT05963984
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-15
Roll-over Study to Allow Continued Access to Ribociclib
CTID: NCT05161195
Phase: Phase 4    Status: Recruiting
Date: 2024-10-15
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
CTID: NCT05631795
Phase: Phase 4    Status: Recruiting
Date: 2024-10-10
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
CTID: NCT05054751
Phase: Phase 3    Status: Completed
Date: 2024-10-10
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
CTID: NCT06635447
Phase: Phase 3    Status: Recruiting
Date: 2024-10-10
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
CTID: NCT04899349
Phase: Phase 2    Status: Terminated
Date: 2024-10-09
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
CTID: NCT04191499
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-10-09
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
CTID: NCT06016738
Phase: Phase 3    Status: Recruiting
Date: 2024-10-08
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
CTID: NCT06630325
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-08
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
CTID: NCT00099437
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-08
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
CTID: NCT06409390
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-10-01
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
CTID: NCT01597388
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-01
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
CTID: NCT05169567
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-26
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
CTID: NCT02028507
Phase: Phase 3    Status: Completed
Date: 2024-09-25
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
CTID: NCT06607757
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-09-23
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
CTID: NCT02913430
PhaseEarly Phase 1    Status: Completed
Date: 2024-09-23
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
CTID: NCT05216432
Phase: Phase 1    Status: Recruiting
Date: 2024-09-23
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
CTID: NCT03006172
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-09-20
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
CTID: NCT05251714
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-09-19
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
CTID: NCT01394016
Phase: Phase 1    Status: Completed
Date: 2024-09-19
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
CTID: NCT02947685
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-19
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
CTID: NCT06179303
Phase: Phase 2    Status: Suspended
Date: 2024-09-19
Phase 1/1b/2 Study of Oral PMD-026 in Patients with Metastatic Breast Cancer
CTID: NCT04115306
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-09-19
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
CTID: NCT02964507
Phase: Phase 1    Status: Terminated
Date: 2024-08-29
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
CTID: NCT02057133
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-08-28
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
CTID: NCT05154487
Phase: Phase 2    Status: Recruiting
Date: 2024-08-23
Endocrine Response in Women With Invasive Lobular Breast Cancer
CTID: NCT02206984
Phase: Phase 2    Status: Completed
Date: 2024-08-22
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
CTID: NCT05384119
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-08-22
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
CTID: NCT06408168
Phase: Phase 2    Status: Recruiting
Date: 2024-08-19
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
CTID: NCT06561022
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-08-19
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
CTID: NCT03531645
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-19
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
CTID: NCT04224272
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-14
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
CTID: NCT04282031
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-08-07
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
CTID: NCT03179904
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-05
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
CTID: NCT02107703
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-08-01
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
CTID: NCT03439046
Phase: Phase 3    Status: Completed
Date: 2024-08-01
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
CTID: NCT04650581
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-07-31
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
CTID: NCT01296555
Phase: Phase 1    Status: Terminated
Date: 2024-07-31
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
CTID: NCT03939897
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-07-30
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
CTID: NCT02476786
Phase: Phase 2    Status: Recruiting
Date: 2024-07-29
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
CTID: NCT02738866
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-25
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
CTID: NCT05870579
Phase: Phase 1    Status: Recruiting
Date: 2024-07-18
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer
CTID: NCT05101564
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-11
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
CTID: NCT05054374
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-07-09
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
CTID: NCT04603183
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-05
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
CTID: NCT05362760
Phase: Phase 4    Status: Recruiting
Date: 2024-06-27
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
CTID: NCT03099174
Phase: Phase 1    Status: Completed
Date: 2024-06-27
VS-6766+Abema+Fulv in Met HR+/HER- BC
CTID: NCT05608252
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-06-25
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
CTID: NCT04862143
Phase: Phase 2    Status: Terminated
Date: 2024-06-20
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
CTID: NCT02955394
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
CTID: NCT05720260
Phase: Phase 2    Status: Recruiting
Date: 2024-06-10
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
CTID: NCT05082025
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-06-10
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
CTID: NCT05524584
Phase: Phase 2    Status: Recruiting
Date: 2024-06-07
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
CTID: NCT02599714
Phase: Phase 1    Status: Completed
Date: 2024-06-06
Detect V / CHEVENDO (Chemo vs. Endo)
CTID: NCT02344472
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-06-04
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
CTID: NCT04300790
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-06-03
Study of AVZO-021 in Patients With Advanced Solid Tumors
CTID: NCT05867251
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-05-30
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
CTID: NCT03926936
Phase: Phase 2    Status: Completed
Date: 2024-05-28
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
CTID: NCT05077449
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-05-24
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
CTID: NCT04092673
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-05-21
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
CTID: NCT04985266
Phase: Phase 2    Status: Recruiting
Date: 2024-05-17
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
CTID: NCT05181033
Phase: Phase 2    Status: Recruiting
Date: 2024-05-17
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
CTID: NCT03767335
Phase: Phase 1    Status: Completed
Date: 2024-05-16
PF-07104091 as a Single Agent and in Combination Therapy
CTID: NCT04553133
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-05-16
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
CTID: NCT04726332
Phase: Phase 1    Status: Terminated
Date: 2024-05-14
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
CTID: NCT06341283
Phase:    Status: Not yet recruiting
Date: 2024-05-10
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
CTID: NCT04738292
Phase: Phase 2    Status: Terminated
Date: 2024-05-03
(VELA) Study of BLU-222 in Advanced Solid Tumors
CTID: NCT05252416
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-04-23
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
CTID: NCT06339281
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-04-19
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
CTID: NCT03781063
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-04-18
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
CTID: NCT05319873
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-04-18
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
CTID: NCT03959891
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-04-16
Aromatase Inhibitor Therapy With
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
CTID: null
Phase: Phase 3    Status: Completed, Trial now transitioned, Ongoing
Date: 2021-11-02
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
CTID: null
Phase: Phase 3    Status: Trial now transitioned, Ongoing
Date: 2021-09-27
A Phase Ib/III Randomised Study of Capivasertib plus CDK4/6i and Fulvestrant versus Placebo plus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer
CTID: null
Phase: Phase 1, Phase 3    Status: Trial now transitioned, Ongoing
Date: 2021-07-14
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
CTID: null
Phase: Phase 2    Status: Completed, Trial now transitioned, Ongoing
Date: 2021-05-31
An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2021-05-24
Open-label, multicenter, pilot-trial evaluating the safety and utility of a hybrid decentralized clinical trial (DCT) approach using a TELEmelse if(down_display === 'none' || down_display === '') { icon_angle_up.style.display = 'none';

相关产品
  • 匹伐加宾
    V40111 69542-93-4 100mg
    Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid analogue with neuromodulatory activity.
    ¥3200.00
  • 磷酸氢化可的松
    V30658 3863-59-0 500mg
    Hydrocortisone phosphate (Hydrocortisone 21-phosphate), a glucocorticoid, is an orally bioactive steroidal anti~inflammatory agent (SAID).
    Get Quote
  • BAY-784
    V40399 1631164-24-3 5mg
    BAY-784 is a novel, potent, orally bioavailable,and selective gonadotropin releasing hormone receptor (GnRH-R) antagonist with IC50s of 21 and 24 nM for human and rat GnRH-R, respectively.
    ¥3000.00
  • Gly-PEG3-endo-BCN
    V38431 2354291-37-3 500mg
    Gly-PEG3-endo-BCN is a PROTAC (PROteolysis TArgeting Chimera) linker of the Polyethylene glycol (PEG) category, may be utilized to prepare PROTAC protein degraders.
    Get Quote
联系我们
电话: 020-31522723 传真: 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member